Key result
Direct cardiac compression devices show promise over traditional mechanical support by avoiding blood-contact complications.
Direct cardiac compression devices are emerging as a promising mechanical cardiac support modality that avoids blood contact complications and maintains arterial pulsatility.
Direct cardiac compression (DCC) devices, under development as a new modality for mechanical cardiac support (MCS), offer several advantages over presently available forms of MCS. DCC devices avoid the blood contact obligatory with other implantable MCS devices, the complications associated with blood contact and hematologic incompatibility, such as thrombosis, stroke, and the need for anticoagulation are avoided, and DCC does not require vascular access eliminating challenges such as bleeding and extremity ischemia. Arterial pressure pulsatility is also maintained with DCC. Significant and underappreciated advancements in DCC technology have occurred over the last decades with notable dramatic improvements in cardiac performance and minimal tissue damage. One device has entered clinical trials with a second device anticipated to follow. DCC is poorly understood by most cardiologists and cardiac surgeons. This review summarizes DCC development and advances so that upcoming human clinical trials can be properly assessed.
No takes yet. Share an insight, caveat, or question.
Hager et al. (2025) conducted a review in Mechanical cardiac support. Direct cardiac compression (DCC) devices vs. Other implantable mechanical cardiac support devices was evaluated. Direct cardiac compression devices offer a promising alternative to traditional mechanical cardiac support by avoiding blood contact and vascular access complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: